Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target
Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
A big investment bank's expert thinks Vertex is a good company to own right now and believes it could be worth more money in the future. When smart investors decide to like a company again, it can mean they found good reasons to feel hopeful about it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.